BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Immune Thrombocytopenia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Immune Thrombocytopen
 ia\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07216079-1477@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07216079)
DESCRIPTION:rilzabrutinib\, phase 3\, Immune Thrombocytopenia.\nStudy: Rilz
 abrutinib for the Adult Participants With Chronic ITP Who Have Completed P
 hase 3 Study in Japan\nEstimated primary completion: 25 November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/rilzabrutinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07216079
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007962-1477@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20271105
DTEND;VALUE=DATE:20271106
SUMMARY:rilzabrutinib: Phase 3 readout est. (NCT07007962)
DESCRIPTION:rilzabrutinib\, phase 3\, Immune Thrombocytopenia.\nStudy: Stud
 y to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With
  Immune Thrombocytopenia (ITP) Who Failed First-line Treatment\nEstimated 
 primary completion: 5 November 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/rilzabrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07007962
URL:https://assetmemo.bio/drug/rilzabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946549-3186@assetmemo.bio
DTSTAMP:20261121T004948Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:CID-103: Phase 2 readout est. (NCT07946549)
DESCRIPTION:CID-103\, phase 2\, Immune Thrombocytopenia.\nStudy: A Study to
  Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune
  Thrombocytopenia\nEstimated primary completion: 30 November 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cid-103#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07946549
URL:https://assetmemo.bio/drug/cid-103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
